A Phase 1/2 interventional study of Tamoxifen and Placebo in Vulvar Atrophy, sponsored by Daré Bioscience, Inc.. Completed at 2 sites in Australia. Open to female participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Daré Bioscience, Inc. · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.
Daré Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women aged 40-75 (inclusive).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaginal insert
Other: Placebo
vaginal insert
Drug: Tamoxifen
vaginal insert
Drug: Tamoxifen
vaginal insert
Drug: Tamoxifen
vaginal insert
Drug: Tamoxifen
Tamoxifen vaginal insert
Placebo vaginal insert
Number of Subjects With Treatment Emergent Adverse Events
to evaluate the safety and tolerability of DARE-VVA1 by intravaginal administration
Time frame: 56 days
Concentration of Tamoxifen in Serial Plasma Collections (Cmax)
to determine the plasma concentrations of tamoxifen after intravaginal administration
Time frame: 56 days
Evaluation of Vaginal Cytology
to analyze the change from baseline to end of study of percentage of parabasal cells
Time frame: 56 days
Evaluation of Vaginal pH
to analyze preliminary efficacy and pharmacodynamics of DARE-VVA1 by looking at change in baseline of vaginal pH from Day 1 to Day 56
Time frame: 56 days
Evaluation of Vaginal Cytology
to analyze the change from baseline to end of study of percentage of superficial cells
Time frame: 56 days
Collection of Menopause-specific Quality of Life (MENQOL) Questionnaire
to analyze the impact of DARE-VVA1 on quality of life following treatment evaluated by total questionnaire score; looking for a decreased in total score.
Time frame: 56 days
| Milestone | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| Started | 4 | 3 | 4 | 3 | 3 |
| Completed | 3 | 3 | 2 | 3 | 3 |
| Not completed | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 2 | 0 | 0 |
to evaluate the safety and tolerability of DARE-VVA1 by intravaginal administration
| Participants | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| Number of Subjects With Treatment Emergent Adverse Events | 3 | 2 | 4 | 3 | 3 |
to determine the plasma concentrations of tamoxifen after intravaginal administration
| ng/mL | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| Concentration of Tamoxifen in Serial Plasma Collections (Cmax) | 0 ± 0 | 0.181 ± 32.21 | 1.93 ± 46.62 | 3.29 ± 12.01 | 5.50 ± 31.54 |
to analyze the change from baseline to end of study of percentage of parabasal cells
| % parabasal cells | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| Evaluation of Vaginal Cytology | 0 (0 to 0) | -12.0 (-15 to -5) | -22.5 (-45 to 0) | -69.0 (-98 to -61) | -94.0 (-100 to -04) |
to analyze preliminary efficacy and pharmacodynamics of DARE-VVA1 by looking at change in baseline of vaginal pH from Day 1 to Day 56
| pH | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| Evaluation of Vaginal pH | -0.3 ± 0.95 | -0.3 ± 0.31 | -0.3 ± 0.42 | -0.3 ± 0.70 | -0.7 ± 0.72 |
to analyze the change from baseline to end of study of percentage of superficial cells
| % superficial cells | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| Evaluation of Vaginal Cytology | 0 (0 to 0) | -3.0 (-4 to -2) | 8.5 (2 to 15) | 6.0 (1 to 14) | 52.3 (18 to 85) |
to analyze the impact of DARE-VVA1 on quality of life following treatment evaluated by total questionnaire score; looking for a decreased in total score.
Results for this outcome have not been posted.
Collected over 56 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| DARE-VVA1 1mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| DARE-VVA1 5mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| DARE-VVA1 10mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| DARE-VVA1 20mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/4 | 1/3 | 2/4 | 1/3 | 1/3 |
| DizzinessNervous system disorders | 2/4 | 0/3 | 1/4 | 0/3 | 0/3 |
| Vulvovaginal discomfortReproductive system and breast disorders | 1/4 | 1/3 | 1/4 | 1/3 | 1/3 |
| Vulvovaginal pruritisReproductive system and breast disorders | 1/4 | 1/3 | 0/4 | 1/3 | 1/3 |
| Genital rashReproductive system and breast disorders | 0/4 | 1/3 | 0/4 | 0/3 | 0/3 |
| Vulvovaginal erythemaReproductive system and breast disorders | 0/4 | 0/3 | 0/4 | 1/3 | 0/3 |
| MigraineNervous system disorders | 0/4 | 1/3 | 0/4 | 0/3 | 0/3 |
| Hot flushVascular disorders | 0/4 | 0/3 | 1/4 | 1/3 | 0/3 |
| Postmenopausal hemorrhageReproductive system and breast disorders | 0/4 | 0/3 | 1/4 | 0/3 | 0/3 |
| SciaticaNervous system disorders | 0/4 | 0/3 | 1/4 | 0/3 | 0/3 |
| Age, Categorical(Participants) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 1 | 4 | 2 | 2 | 12 |
| >=65 years | 1 | 2 | 0 | 1 | 1 | 5 |
| Age, Continuous(years) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| Mean | 61.3 ± 5.38 | 65.7 ± 1.53 | 59.3 ± 2.99 | 57.7 ± 8.08 | 61.3 ± 4.16 | 60.9 ± 4.97 |
| Sex: Female, Male(Participants) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 3 | 3 | 17 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 3 | 4 | 3 | 3 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 3 | 4 | 3 | 3 | 17 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| Australia | 4 | 3 | 4 | 3 | 3 | 17 |
| Body Mass Index(kg/m^2) | Placebo | DARE-VVA1 1mg | DARE-VVA1 5mg | DARE-VVA1 10mg | DARE-VVA1 20mg | Total |
|---|---|---|---|---|---|---|
| Mean | 25.03 ± 5.287 | 26.04 ± 4.869 | 26.58 ± 5.486 | 24.67 ± 2.219 | 23.70 ± 3.676 | 25.27 ± 4.151 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — A decision has not yet been made on when or what IPD to share when available.
Ran from Nov 2021 to primary completion in Dec 2022, 12 months.
Results were first posted in Oct 2024, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamoxifen
Daré Bioscience, Inc.